Manuscript:

Introduction : Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma. Patients may have a variable clinical presentation and it may be nodal or extranodal. The 4th edition World Health Organization (WHO) guidelines for tumors of hematopoietic and lymphoid tissues, 2008 defined DLBCL as neoplasm of large B-cell arranged in a diffuse pattern.1 In 2016 it was revised and updated to include details on cell of origin classification (COO), CD5 expression on prognosis, double expressor lymphoma (DEL) and further understanding of high grade-B cell lymphoma.2
The diagnoses for most cases of lymphoma are managed with biopsies and the support of immunohistochemical (IHC) markers. CD3 and CD20, are membranous stains and the most basic initial step in identifying T and B cell lymphoma. However, the diagnosis can sometimes be challenging, like the cases described here where steroids may alter the antigen expression of the neoplasm and present a major challenge clinically and diagnostically for pathologists. We have discussed the implications of steroid use and the importance of sound knowledge of staining patters of different antibodies to correctly interpret membrane and nuclear staining antibodies also highlighting the importance of proper controls.